Ketamine & Esketamine

Traditional antidepressants take months of daily use before you feel better — and for someone out of options and thinking about ending it, time is the one thing they don't have. Ketamine works in a completely different way from the old drugs, and it delivers results within hours. This lesson explains how it works at the level of the brain, why it's the only "psychedelic-style psychiatric drug" that's already FDA-approved and making real money in the billions — and the limits worth stating plainly.

Theme index · base 100 · USD total return
News & notes moving Ketamine & Esketamine
Ketamine & Esketamine

Sinopharm Modern's Wholly-Owned Subsidiary Gets Approval for Esketamine Hydrochloride API

Sinopharm Modern announced that its wholly-owned subsidiary Sinopharm Industrial received the Chemical API Marketing Application Approval Notice issued by the National Medical Products Administration, approving the marketing application for esketamine hydrochloride API. Esketamine is a non-selective NMDA receptor antagonist, an anesthetic and analgesic drug commonly used in surgical anesthesia, pain management, and treatment of treatment-resistant depression.
600420.CG
Psychedelic Medicine
Jiemian·23dRead more →
Ketamine & Esketamine▲4

NRx Pharma rises as FDA completes initial review of ketamine product

Shares of NRx Pharmaceuticals rose after the FDA completed an initial review of its marketing application for a preservative-free ketamine product without identifying any major drug-related deficiencies. The regulator did not require new clinical or drug-related findings to prove safety and efficacy, but it classified a question about the luer lock tip of the medication vial as a major deficiency. Following a clarification meeting on August 6, NRx Pharma cited a substantially de-risked path to approval, noting that three ANDA-approved products on the market use the same luer-lock vial. CEO Jonathan Javitt said the company is encouraged by the FDA's commitment to review the remaining information in the shortest possible cycle.
Psychedelic Medicine ▲
Seeking Alpha·42dRead more →
Ketamine & Esketamine▲10impact 4

Eli Lilly to acquire AtaiBeckley for $2.8 billion

Eli Lilly is acquiring psychedelic drug developer AtaiBeckley for $2.8 billion. The deal, which could be valued at up to $3.8 billion, marks a significant move into psychedelic-based mental health treatments. Mizuho Americas healthcare equity strategist Jared Holz noted that large-cap pharma is increasingly embracing alternative therapies, citing J&J's ketamine-based product annualizing nearly $2 billion. Holz expects 2025 to be a historic year for biotech M&A, with over 30 transactions north of a billion dollars.
LLY ▲ATAI ▲
Psychedelic Medicine ▲Biotech & Genomic Medicine ▲
Yahoo Finance·64dRead more →
Ketamine & Esketamine2

AtaiBeckley Joins Russell 2000 and 3000 Indices, Canaccord Raises Price Target to $17

AtaiBeckley N.V. will be added to the Russell 2000 and Russell 3000 indices effective June 29, a move the company notes is significant given over $12 trillion in assets benchmarked to Russell indexes. Canaccord Genuity subsequently raised its price target on the stock from $15 to $17 on July 7, implying more than 227% upside, while reiterating a Buy rating. The revision followed completion of dosing in the Phase 2 Elumina trial of VLS-01 for treatment-resistant depression, with the company targeting Phase 3 development for major depressive disorder and potential expansion into generalized anxiety disorder. AtaiBeckley is a clinical-stage biopharmaceutical company focused on mental health therapies, with a pipeline that includes BPL-003 in Phase 2 for treatment-resistant depression and alcohol addiction, and RL-007 for cognitive decline from schizophrenia.
ATAI ▲
Psychedelic Medicine
Insider Monkey·65dRead more →
Ketamine & Esketamine

Three Psychedelic Stocks With Potential Clinical Trial Catalysts

Optimi Health, AtaiBeckley, and COMPASS Pathways are three psychedelic medicine companies with upcoming clinical trial catalysts that could reshape their risk-reward profiles. Optimi Health, a Canadian manufacturer with a Health Canada-licensed GMP facility, is already shipping pharmaceutical-grade MDMA and psilocybin into Australia's reimbursed prescription market, though its revenue remains below CA$1 million. AtaiBeckley has multiple Phase 2 programs targeting treatment-resistant depression and social anxiety, with Phase IIb data expected in 2026 and potential progression to Phase 3 trials, but it faces widening losses and high funding risk. COMPASS Pathways is advancing its psilocybin therapy COMP360 in Phase III for treatment-resistant depression and plans to file a rolling NDA with the FDA, yet it remains pre-revenue with a history of shareholder dilution.
OPTH ▲ATAI
Psychedelic Medicine
Simply Wall St·71dRead more →
© 2026 MarketDXExplore